Merus Labs International Inc. (TSE:MSL – Free Report) (NASDAQ:MSLI) – HC Wainwright lowered their FY2024 earnings per share (EPS) estimates for Merus Labs International in a research report issued on Monday, November 18th. HC Wainwright analyst A. He now anticipates that the specialty pharmaceutical company will post earnings of ($0.24) per share for the year, down from their previous forecast of ($0.20). HC Wainwright also issued estimates for Merus Labs International’s FY2027 earnings at ($0.25) EPS.
Merus Labs International Stock Performance
The stock has a fifty day moving average of C$1.65. Merus Labs International has a 1-year low of C$0.95 and a 1-year high of C$1.76.
About Merus Labs International
Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin.
Further Reading
- Five stocks we like better than Merus Labs International
- How to Choose Top Rated Stocks
- Target Results Are Not a Retail Bellwether: Why the Dip Is a Buy
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Williams-Sonoma Stock: Buy It and Never Let It Go
- Using the MarketBeat Dividend Tax Calculator
- 5 Dividend ETFs to Buy and Hold Forever
Receive News & Ratings for Merus Labs International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International and related companies with MarketBeat.com's FREE daily email newsletter.
